Saturday 17 October 2026
Export BNR’s income statement to Excel — free account
Burning Rock Biotech Limited Sponsored ADR
BNR Healthcare Diagnostics & Research
Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024. In the quarter to June 2026, revenue fell 4.22%, EPS fell 98.4%, free cash flow grew 46.0% and total debt fell 5.02%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
12.69
2.91
−18.65%
Follow BNR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
12.35 | 22.79 | 2.78 | 1.26 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(270.14) | (399.44) | 67.70 | 41.55 | |
P/B ratio |
12.41 | 22.66 | 2.80 | 1.21 | |
Price to Tangible BV |
12.41 | 22.67 | 2.80 | 1.21 | |
EV/Sales |
11.52 | 21.97 | 1.89 | 0.41 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(384.18) | (322.44) | (35.81) | (7.47) | |
EV/FCF |
(57.87) | (93.43) | (8.83) | (1.35) | |
Quick Ratio |
2.72 | 2.67 | 2.63 | 2.77 | |
Current Ratio |
3.05 | 3.05 | 2.99 | 3.14 | |
Net Debt/EBITDA |
23.18 | 22.24 | 36.47 | 27.91 | |
Debt/Assets |
0.24% | 3.78% | 0.23% | 2.04% | |
Debt/Equity |
0.00 | 0.06 | 0.00 | 0.03 | |
Asset Turnover |
0.65 | 0.64 | 0.65 | 0.58 | |
Operating CF/Net income |
1.24 | 1.68 | (1.35) | (0.95) | |
Capex/Depreciation |
— | — | (0.20) | — | |
Interest Coverage |
(1,326.50) | (1,365.50) | (939.50) | (1,133.50) | |
Research and Development Expense of Revenue |
23.17% | 25.53% | 27.91% | 31.51% | |
Selling, General and Administrative Expense of Revenue |
62.76% | 64.20% | 59.35% | 55.85% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.07 | 0.04 | 0.30 | 0.72 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.20%) | (3.14%) | (2.48%) | (15.84%) | |
Free Cash Flow Yield |
(1.61%) | (1.03%) | (7.71%) | (23.81%) | |
Revenue per Share |
0.18 | 0.15 | 1.84 | 1.72 | |
Operating CF per Share |
(0.03) | (0.04) | 0.30 | 0.21 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.03) | (0.04) | 0.30 | 0.21 | |
Cash per Share |
0.57 | 0.62 | 6.47 | 6.09 | |
Shareholders Equity per Share |
0.67 | 0.71 | 7.20 | 7.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.67 | 0.71 | 7.20 | 7.17 | |
Free Cash Flow |
(3.36) | (4.25) | 3.16 | 2.24 | |
Working Capital |
65.80 | 68.31 | 70.30 | 70.83 | |
Capital Expenditures |
— | — | (0.63) | — | |
Net Current Asset Value |
60.50 | 62.29 | 64.85 | 66.97 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
25.99 | 22.91 | 22.54 | 24.77 | |
Average Payables |
3.57 | 3.78 | 5.22 | 4.20 | |
Average Inventory |
6.55 | 8.44 | 7.76 | 8.56 | |
Average Assets |
112.89 | 115.99 | 119.30 | 127.21 | |
Average Common Equity |
76.01 | 76.83 | 78.06 | 84.78 |
Columns are period end dates